Design and evaluation of polymer coated carvedilol loaded solid lipid nanoparticles to improve the oral bioavailability: A novel strategy to avoid intraduodenal administration

Colloids and Surfaces B: Biointerfaces

Volumn 95, Issue , 2012, Pages 1-9

  Venishetty, Vinay Kumar ^a,b   Chede, Raghavendra ^a   Komuravelli, Rojarani ^b   Adepu, Laxminarayana ^a   Sistla, Ramakrishna ^a   Diwan, Prakash V ^a  

^a INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Bioavailability; Carvedilol; Entrapment efficiency; N carboxymethyl chitosan; Solid lipid nanoparticles; Stearylamine

Indexed keywords

BIOAVAILABILITY; CARVEDILOL; ENTRAPMENT EFFICIENCY; SOLID LIPID NANOPARTICLE (SLN); STEARYLAMINE;

BIOCHEMISTRY; CHITOSAN; NANOPARTICLES; PHOSPHOLIPIDS; POLYMER BLENDS; POLYMERS; SPECTROSCOPIC ANALYSIS; SURFACE ACTIVE AGENTS; ZETA POTENTIAL;

PLASTIC COATINGS;

CARVEDILOL; CHITOSAN DERIVATIVE; MONOACYLGLYCEROL; N CARBOXYMETHYLCHITOSAN; OCTADECYLAMINE; PHOSPHATIDYLCHOLINE; POLOXAMER; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG COATING; DRUG STABILITY; ENCAPSULATION; INTESTINE FLUID; LIPOPHILICITY; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NONHUMAN; PARTICLE SIZE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RAT; ROENTGEN SPECTROSCOPY; SIMULATION; STOMACH JUICE; SURFACE CHARGE; TIME TO MAXIMUM PLASMA CONCENTRATION; X RAY DIFFRACTION; ZETA POTENTIAL;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CARBAZOLES; CHITOSAN; COATED MATERIALS, BIOCOMPATIBLE; DRUG DESIGN; DUODENUM; INJECTIONS, INTRAVENOUS; LIPIDS; MALE; MOUTH; NANOPARTICLES; ORGAN SPECIFICITY; PARTICLE SIZE; POLYMERS; POWDER DIFFRACTION; PROPANOLAMINES; RATS; RATS, WISTAR;

RATTUS;

EID: 84860570421     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2012.01.001     Document Type: Article

References (22)

1. Mehnert W., Mader K. Solid lipid nanoparticles: production, characterization and applications. Adv. Drug Deliv. Rev. 2001, 47:165-196.
2. Manjunath K., Venkateswarlu V. Pharmacokinetics, tissue distribution and bioavailability of nitrendipine solid lipid nanoparticles after intravenous and intraduodenal administration. J. Drug Target 2006, 14:632-645.
3. Kumar V.V., Chandrasekar D., Ramakrishna S., Kishan V., Rao Y.M., Diwan P.V. Development and evaluation of nitrendipine loaded solid lipid nanoparticles: influence of wax and glyceride lipids on plasma pharmacokinetics. Int. J. Pharm. 2007, 335:167-175.
4. Venkateswarlu V., Manjunath K. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J. Control Release 2004, 95:627-638.
5. Bargoni A., Cavalli R., Caputo O., Fundaro A., Gasco M.R., Zara G.P. Solid lipid nanoparticles in lymph and plasma after duodenal administration to rats. Pharm. Res. 1998, 15:745-750.
6. Cavalli R., Bargoni A., Podio V., Muntoni E., Zara G.P., Gasco M.R. Duodenal administration of solid lipid nanoparticles loaded with different percentages of tobramycin. J. Pharm. Sci. 2003, 92:1085-1094.
7. Manjunath K., Venkateswarlu V. Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J. Control Release 2005, 107:215-228.
8. Parfitt K. Martindale The Complete Drug Reference 1999, Pharmaceutical Press, London, p. 838.
9. Bernkop-Schnurch A. Chitosan and its derivatives: potential excipients for peroral peptide delivery systems. Int. J. Pharm. 2000, 194:1-13.
10. Muzzarelli R.A.A., Tanfani F., Emanuelli M., Mariotti S. N-(carboxymethylidene)chitosans and N-(carboxymethyl)chitosans: novel chelating polyampholytes obtained from chitosan glyoxylate. Carbohydr. Res. 1982, 107:199-214.
11. Di Colo G., Zambito Y., Burgalassi S., Nardini I., Saettone M.F. Effect of chitosan and of N-carboxymethylchitosan on intraocular penetration of topically applied ofloxacin. Int. J. Pharm. 2004, 273:37-44.
12. Thanou M., Nihot M.T., Jansen M., Verhoef J.C., Junginger H.E. Mono-N-carboxymethyl chitosan (MCC) a polyampholytic chitosan derivative, enhances the intestinal absorption of low molecular weight heparin across intestinal epithelia in vitro and in vivo. J. Pharm. Sci. 2001, 90:38-46.
13. Hokama N., Hobara N., Sakai M., Kameya H., Ohshiro S., Sakanashi M. Influence of nicardipine and nifedipine on plasma carvedilol disposition after oral administration in rats. J. Pharm. Pharmacol. 2002, 54:821-825.
14. Rathod R., Prasad L.P., Rani S., Nivsarkar M., Padh H. Estimation of carvedilol in human plasma by using HPLC-fluorescence detector and its application to pharmacokinetic study. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2007, 857:219-223.
15. Abreu F.R.d., Campana-Filho S.r.P. Preparation and characterization of carboxymethylchitosan. Polã-meros 2005, 15:79-83.
16. Reddy L.H., Murthy R.S. Etoposide-loaded nanoparticles made from glyceride lipids: formulation, characterization, in vitro drug release, and stability evaluation. AAPS Pharm. Sci. Tech. 2005, 6:E158-E166.
17. Porter C.J.H., Charman W.N. Intestinal lymphatic drug transport: an update. Adv. Drug Delivery Rev. 2001, 50:61-80.
18. Muller R.H., Mader K., Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur. J. Pharm. Biopharm. 2000, 50:161-177.
19. Wissing S.A., Kayser O., Muller R.H. Solid lipid nanoparticles for parenteral drug delivery. Adv. Drug Deliv. Rev. 2004, 56:1257-1272.
20. Mansbach C.M., Nevin P. Intracellular movement of triacylglycerols in the intestine. J. Lipid Res. 1998, 39:963-968.
21. Sanjula B., Shah F.M., Javed A., Alka A. Effect of poloxamer 188 on lymphatic uptake of carvedilol-loaded solid lipid nanoparticles for bioavailability enhancement. J. Drug Target 2009, 17:249-256.
22. Almeida A.J., Souto E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv. Drug Deliv. Rev. 2007, 59:478-490.